Long-term memory study for people with early Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study looks at the long-term effects of the Alzheimer's drug LEQEMBI (lecanemab) in people with mild memory problems or early Alzheimer's. It gathers information from patients who have already been taking the drug for 18 months to see how they are doing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia.
- You have been taking the drug LEQEMBI for 18 months and completed a memory assessment at that time.
- You must have had a memory assessment before starting LEQEMBI.
- You are not a carrier of two copies of the APOE4 gene (you are either a heterozygous carrier or noncarrier).
- You have not used another anti-amyloid treatment during the 18-month period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
This study looks at people who are taking or have taken lecanemab (a medication for Alzheimer's disease). It aims to gather more information about the treatment's effects in real-world settings.
This study tracks the safety of Leqembi (lecanemab), a treatment for Alzheimer's disease, in people who are already prescribed it in the UK. It helps doctors learn more about how the medicine affects patients in everyday life.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study observes people with Alzheimer's disease who are taking leqembi in Taiwan to learn more about how it works in everyday use. It may help understand the treatment's benefits and risks outside of clinical trials.
This study tests a new treatment, called X/T, for people with Alzheimer's disease who are already taking lecanemab (Leqembi). The goal is to see if adding X/T is safe and tolerable, and if it might help manage symptoms.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.